Program HighlightThe 1st Annual Cell Therapy Industry Summit will provide an excellent opportunity for thought leaders to celebrate cell therapy industry achievements and disseminate best practices. The meeting is designed specifically to serve the networking and informational needs of cell therapy industry leaders and limited in attendance to ensure participants are able to engage in meaningful discussions about mutually beneficial industry trends, dynamics and opportunities.
 |
 |
- Greg Lucier, Chairman and CEO , Life Technologies Corporation
- Tom Okarma, President and CEO, Geron Corporation
- Geoff MacKay, President and CEO, Organogenesis Inc.
- Edward Lanphier, President and CEO, Sangamo BioSciences, Inc.
- Neil K. Warma, President & CEO, Opexa Therapeutics, Inc.
- James Noble, CEO, Adaptimmune Ltd.
- Deborah Eppstein, President, CEO, and Director, Q Therapeutics, Inc
- Robert J. Harman, Founder and CEO, Vet-Stem
- Duane J. Roth, CEO and member of the Board of CONNECT
- Eduardo Bravo, CEO, Cellerix
- Alan Trounson, President, California Institute for Regenerative Medicine
- Edward L. Field, President and COO, Aldagen
- Robert A. Preti, President and CSO, Progenitor Cell Therapy LLC
- Allan Robins, Vice President and CTO, Novocell, Inc.
- Weng Tao, Vice President, Research & Development and CSO, Neurotech
- Michael Schuster, Vice President of Operation, Angioblast Systems, Inc.
- Vern L. Liebmann, Vice President, Operations, Aderans Research
| | - Dushyant Pathak, Vice President of Business Development, iPierian, Inc.
- Tom Novak, Head of Discovery Technologies, Roche Palo Alto
- Kenneth K. Kleinhenz, Vice President of Regulatory Affairs, Cytori Therapeutics Inc.
- Nicole Provost, Vice President of Product Development, Dendreon Corporation
- Rajesh Chopra, Vice President of Translational Research, Celgene Corporation
- Jason Krentz, Executive Director, Technical Operations, Tengion, Inc.
- Katie Faria, Director of Process Development, Organogenesis Inc.
- David DiGiusto, Director of Cellular Process Development and Manufacturing, City of Hope National Medical Center
- Ron Jankowski, Director of Research and Product Development, Cook MyoSite
- Wouter Van’t Hof, Director of Regenerative Medicine, Athersys, Inc.
- Juliana Blum, Director of Business Operations and Co-founder, Humacyte, Inc.
- Ralph Brandenberger, Director Process Sciences, Geron Corporation
- Doris Taylor, Director of the Center for Cardiovascular Repair, University of Minnesota
- Joyce L. Frey-Vasconcells, Executive Director, Pharmanet Consulting
|
 |
| WEDNESDAY, NOVEMBER 11 | | 6:00pm - 9:00pm | Pre-conference networking event & cocktail reception | | | | THURSDAY, NOVEMBER 12 | | 7:00am - 8:00am | Breakfast | | 8:00am - 10:00am | Session 1: Leading in regenerative medicine. | | | • Shaping the regulatory environment through scientific excellence • Personalized medicine in action • Driving shareholder value through cell therapy Moderator: Greg Lucier, Life Technologies Corporation Speakers: Tom Okarma, Geron Corporation Geoff MacKay, Organogenesis, Inc Eduardo Bravo, Cellerix Alan Trounson, California Institute for Regenerative Medicine | | 10:00am - 10:30am | Morning Coffee | | 10:30am - 12:00pm | Session 2: Stepping into regenerative medicine. | | | • Growth opportunities in cell therapy • Barriers investment in cell therapy • Partnership models for success Moderator: Paul Pickering, Life Technologies Corporation Speakers: Tom Novak, Roche Palo Alto Rajesh Chopra, Celgene Corporation Neil K. Warma, Opexa Therapeutics, Inc | | 12:00pm - 1:00pm | Lunch | | 1:00pm - 2:30pm | Breakout Sessions | | | Session 1: Gene modification Gene modification systems and processes, vector design and production issues, safety and regulatory concerns, and the future of cell-based gene therapy Moderator: Mark Bonyhadi, Life Technologies Corporation Speakers: Dave DiGuisto, City of Hope Weng Tao, Neurotech Edward Lanphier, Sangamo BioSciences, Inc James Noble, Adaptimmune Ltd. Session 2: Stem cell scale up Scale up considerations and technologies critical for providing stem cells at phase appropriate levels to support development from pre-clinical evaluations through commercialization Moderator: Eric Roos, Life Technologies Corporation Speakers: Ralph Brandenberger, Geron Corporation Wouter Vant Hof, Athersys, Inc Allan Robins, Novocell, Inc Session 3: More with less Efforts to economize cell therapy manufacturing through items such as raw material sourcing, process efficiencies and automation. Moderator: Brian Newsom, Life Technologies Corporation Speakers: Katie Faria, Organogenesis Ron Jankowski, Cook MyoSite Juliana Blum, Humancyte Jason Krentz, Tengion, Inc. | | 2:30pm - 3:00pm | Afternoon Break | | 3:00pm - 5:00pm | Session 4: Models for expedited commercialization. | | | • Opportunities for expedited regulatory clearance • Novel go-to-market strategies • Cash flow positive business models which build to therapeutic outcomes Moderator: Joydeep Goswami, Life Technologies Corporation Speakers: Dushyant Pathak, iPierian, Inc. Kenneth K. Kleinhenz, Cytori Therapeutics Duane J. Roth, CONNECT Joyce L. Frey-Vasconcells, Pharmanet Consulting | | 5:30pm - 8:00pm | Networking reception and Dinner | | | | FRIDAY, NOVEMBER 13 | | 7:00am - 8:00am | Breakfast | | 8:00am - 10:00am | Session 1: Expanding your business with novel cell therapy platforms. | | | • Point of care for autologous therapy • Novel differentiated cell populations • Mobilization of endogenous progenitor Moderator: Mahendra Rao, Life Technologies Corporation Speakers: Deborah Eppstein, Q Therapeutics Doris Taylor, University of Minnesota Nicole Provost, Dendreon Robert J. Harman, Vet-Stem | | 10:00am - 10:30am | Morning Coffee | | 10:30am - 12:00pm | Session 2: Building a sustainable cell therapy business: The make vs. buy decision. | | | • Key parameters to consider in making your decision • The influence of clinical development stage • How to smooth the transition between manufacturing models Moderator: Nicolas Barthelemy, Life Technologies Corporation Speakers: Vern L. Liebmann, Aderans Research Edward L. Field, Aldagen Robert A. Preti, Progenitor Cell Therapy LLC Michael Schuster, Angioblast Systems, Inc. |
 |
 |
| |
Event Information
|